We use cookies to improve your experience and for marketing. Read our cookie policy or manage cookies.

Accept essential cookies
Accept all cookies
View All

Blog - Vaccines For Human Medicine

GlaxoSmithKline's Promising Outlook Amid Concerns
GlaxoSmithKline's Promising Outlook Amid Concerns
Feb 11, 2025
Eye 29

GlaxoSmithKline (GSK) unveils a promising 2025 outlook with strategic initiatives in drug development and a £2 billion share buyback plan, despite challenges in vaccine sales.
Merck Suspends Gardasil Shipments to China
Merck Suspends Gardasil Shipments to China
Feb 4, 2025
Eye 44

Merck has temporarily halted Gardasil shipments to China due to reduced demand, impacting 2025 revenue forecasts, while Keytruda sales remain strong.
Merck's Earnings Align with Expectations, Stock Declines on 2025 Forecast
Merck's Earnings Align with Expectations, Stock Declines on 2025 Forecast
Feb 4, 2025
Eye 61

Merck's earnings aligned with Wall Street expectations, yet stocks fell due to a lackluster 2025 forecast. The company's reliance on products like Gardasil and Keytruda amid Chinese market challenges is under scrutiny.
Experts Predict Smaller Winter COVID Wave in U.S., Impacting Pfizer's Growth
Experts Predict Smaller Winter COVID Wave in U.S., Impacting Pfizer's Growth
Feb 3, 2025
Eye 113

U.S. experts predict a smaller winter COVID wave, posing challenges for Pfizer amid declining revenues, emphasizing the need to diversify non-COVID products.
AstraZeneca Abandons £450m Vaccine Facility Development in the UK
AstraZeneca Abandons £450m Vaccine Facility Development in the UK
Jan 31, 2025
Eye 99

AstraZeneca has abandoned plans for a £450m vaccine facility in the UK, highlighting economic and funding challenges. Learn about the implications for UK's life sciences sector.
Sanofi's Strategic Share Buyback Amid Robust Q4 Performance
Sanofi's Strategic Share Buyback Amid Robust Q4 Performance
Jan 30, 2025
Eye 115

Sanofi reports a strong fourth-quarter performance, aligns with profit expectations, and announces a significant share buyback, highlighting growth in its drug pipeline and sales.
Moderna's Norovirus Vaccine Trial Advances Amid Surge in U.S. Cases
Moderna's Norovirus Vaccine Trial Advances Amid Surge in U.S. Cases
Jan 23, 2025
Eye 241

Explore Moderna's ongoing phase three norovirus vaccine trial targeting urgent prevention needs amid rising outbreaks in the U.S.
Moderna Secures an Additional $590 Million for Influenza Vaccine Development
Moderna Secures an Additional $590 Million for Influenza Vaccine Development
Jan 18, 2025
Eye 208

Moderna has secured $590 million to enhance pandemic influenza vaccine development, focusing on mRNA technology and expanding human trials.
Moderna Revises 2025 Sales Forecast Amid Weak Vaccine Demand
Moderna Revises 2025 Sales Forecast Amid Weak Vaccine Demand
Jan 13, 2025
Eye 105

Moderna cuts 2025 sales forecast by $1 billion due to weak RSV and COVID-19 vaccine demand, prompting strategic shifts and cost reductions.
Moderna Shares Surge Amid H5N1 Vaccine Development
Moderna Shares Surge Amid H5N1 Vaccine Development
Jan 7, 2025
Eye 92

Moderna's shares increased by over 10% due to progress in H5N1 vaccine development following a human fatality in the U.S.
Novavax to Divest Czech Facility to Novo Nordisk for $200 Million
Novavax to Divest Czech Facility to Novo Nordisk for $200 Million
Dec 4, 2024
Eye 397

Novavax sells its Czech manufacturing facility to Novo Nordisk for $200 million, focusing on strengthening its vaccine pipeline and operational efficiency.
The Netherlands Sees a Major Decline in Vaccine Imports, Dropping to $712 Million in 2023
The Netherlands Sees a Major Decline in Vaccine Imports, Dropping to $712 Million in 2023
Oct 3, 2024
Eye 145

The growth of imports for Vaccines from 2021 to 2023 did not pick up steam, with vaccine imports decreasing to $712M in 2023.
Show more